Open menu

Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: January 27, 2009

Concurrent Analytical Inc. Receives Phase I SBIR Grant from NSF

(Nanowerk News) In an effort to combat the near epidemic levels in HSV in the world, Concurrent Analytical Inc. was recently selected by the National Science Foundation (NSF) to modify its current Ramanprobes™ system for use in detecting both types 1 and 2 in a high speed, low cost platform capable of quantifying HSV levels critical to diagnosis.
The Concurrent Analytical Ramanprobes System
The Concurrent Analytical Ramanprobes System
The broader impacts of this research are demonstrated by the urgent need for reliable techniques that can be deployed as rapid, low-cost analysis methods ranging from point-of-care (POC) diagnostics in the doctor’s office or hospital, to laboratory testing. Presently more than 50 million Americans have genital herpes, with another 1% of the U.S. population predicted to become infected annually. A 1999 survey showed ~20% of pregnant women tested positively for HSV-2 antibodies. If economic and rapid POC testing were available as a litmus test for HSV-2 in maternity wards, more informed decisions for herpes necessitated cesarean deliveries could be made, thereby protecting the immune-compromised neonates. A technique capable of quantifying HSV at the noted levels would also find a niche in the researcher’s laboratory in evaluating the antiviral effectiveness of candidate vaccines, as well as by pathologists in defining infective pathogen thresholds.
Dr. Christian Schoen, President of Concurrent Analytical Inc., is interested in using the Ramanprobes™ system for ultrasensitive diagnostic tests such as the early detection of cancer. The system has already been used for diagnostics in Prostate Specific Antigen, and more recently, in detecting Pancreatic Cancer.
Pancreatic Cancer is the fourth leading cause of cancer related deaths and claims 30,000 American lives each year. The five year survival rate is less than 5% and most patients die within the first two years. The Ramanprobes™ system has detected Pancreatic Cancer earlier than any other diagnostic. So early in fact, the diagnostic is opening up the opportunity for treatment.
"We are very excited at developing these diagnostics tests. These tests will be able to allow doctors to quickly and easily detect cancers and viruses at a very early stage” said Dr. Schoen.
Dr. Marc Porter, Director of the USTAR Nanotechnology Biosensors Group at the University, along with ARUP, Inc. (Salt Lake City, UT), are partners in the effort.
Concurrent Analytical Inc. has seen tremendous success mostly due to development funding support from the National Defense Center of Excellence for Research in Ocean Sciences (CEROS), a division of DARPA located in Hawaii.
A division of Concurrent Analytical Inc., Nanopartz (www.nanopartz.com) sells gold nanoparticles, gold nanorods, and gold nanowires to the research industry. More recently, Concurrent Analytical Inc. split off Resonance Therapeutics Inc. (www.resonancetherapeutics.com) for developing cancer therapy techniques utilizing gold nanorods.
For more information, visit Concurrent Analytical Inc. at www.concana.com.
Source: Concurrent Analytical (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
 
 
If you liked this article, please give it a quick review on reddit or StumbleUpon. Thanks!
 
 
These articles might interest you as well: